{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:10:28Z","timestamp":1791385828185,"version":"4.3.3"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T00:00:00Z","timestamp":1553126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T00:00:00Z","timestamp":1553126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2018M3A9F1023697"],"award-info":[{"award-number":["NRF-2018M3A9F1023697"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2014M3C7A1064752"],"award-info":[{"award-number":["NRF-2014M3C7A1064752"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2018M3A9F1023697"],"award-info":[{"award-number":["NRF-2018M3A9F1023697"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI18C0479"],"award-info":[{"award-number":["HI18C0479"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007033","name":"Eisai | Eisai Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007033","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We investigated the level of amyloid beta (A\u03b2) in nasal secretions of patients with Alzheimer\u2019s disease dementia (ADD) using interdigitated microelectrode (IME) biosensors and determined the predictive value of A\u03b2 in nasal secretions for ADD diagnosis. Nasal secretions were obtained from 35 patients with ADD, 18 with cognitive decline associated with other neurological disorders (OND), and 26 cognitively unimpaired (CU) participants. Capacitance changes in IMEs were measured by capturing total A\u03b2 (\u0394C<jats:sub>tA\u03b2<\/jats:sub>). After 4-(2-hydroxyethyl)-1-piperazinepropanesulfonic acid (EPPS) was injected, additional capacitance changes due to the smaller molecular weight A\u03b2 oligomers disassembled from the higher molecular weight oligomeric A\u03b2 were determined (\u0394C<jats:sub>oA\u03b2<\/jats:sub>). By dividing two values, the capacitance ratio (\u0394C<jats:sub>oA\u03b2<\/jats:sub>\/\u0394C<jats:sub>tA\u03b2<\/jats:sub>) was determined and then normalized to the capacitance change index (CCI). The CCI was higher in the ADD group than in the OND (p\u2009=\u20090.040) and CU groups (p\u2009=\u20090.007). The accuracy of the CCI was fair in separating into the ADD and CU groups (area under the receiver operating characteristic curve\u2009=\u20090.718, 95% confidence interval\u2009=\u20090.591\u20130.845). These results demonstrate that the level of A\u03b2 in nasal secretions increases in ADD and the detection of A\u03b2 in nasal secretions using IME biosensors may be possible in predicting ADD.<\/jats:p>","DOI":"10.1038\/s41598-019-41429-1","type":"journal-article","created":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T11:12:55Z","timestamp":1553166775000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Amyloid beta in nasal secretions may be a potential biomarker of Alzheimer\u2019s disease"],"prefix":"10.1038","volume":"9","author":[{"given":"Young Hyo","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Myung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungbo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Hee","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang-Ki","family":"Minn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyelim","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4180-8626","authenticated-orcid":false,"given":"Seong Hye","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,21]]},"reference":[{"issue":"Suppl 1","key":"41429_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1017\/S1041610297004675","volume":"9","author":"B Reisberg","year":"1997","unstructured":"Reisberg, B. et al. Diagnosis of Alzheimer\u2019s disease. Report of an International Psychogeriatric Association Special Meeting Work Group under the cosponsorship of Alzheimer\u2019s Disease International, the European Federation of Neurological Societies, the World Health Organization, and the World Psychiatric Association. Int. Psychogeriatr. 9(Suppl 1), 11\u201338 (1997).","journal-title":"Int. Psychogeriatr."},{"key":"41429_CR2","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","volume":"368","author":"K Blennow","year":"2006","unstructured":"Blennow, K., de Leon, M. J. & Zetterberg, H. Alzheimer\u2019s disease. Lancet 368, 387\u2013403 (2006).","journal-title":"Lancet"},{"key":"41429_CR3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.trci.2018.03.009","volume":"4","author":"J Cummings","year":"2018","unstructured":"Cummings, J., Lee, G., Ritter, A. & Zhong, K. Alzheimer\u2019s disease drug development pipeline: 2018. Alzheimers Dement. (N Y) 4, 195\u2013214 (2018).","journal-title":"Alzheimers Dement. (N Y)"},{"key":"41429_CR4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","volume":"370","author":"RS Doody","year":"2014","unstructured":"Doody, R. S. et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s diseas. e. N. Engl. J. Med. 370, 311\u2013321 (2014).","journal-title":"e. N. Engl. J. Med."},{"key":"41429_CR5","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway, S. et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N. Engl. J. Med. 370, 322\u2013333 (2014).","journal-title":"N. Engl. J. Med."},{"key":"41429_CR6","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2015.4668","volume":"313","author":"WJ Jansen","year":"2015","unstructured":"Jansen, W. J. et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. J.A.M.A. 313, 1924\u20131938 (2015).","journal-title":"J.A.M.A."},{"key":"41429_CR7","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ana.20009","volume":"55","author":"WE Klunk","year":"2004","unstructured":"Klunk, W. E. et al. Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh Compound-B. Ann. Neurol. 55, 306\u2013319 (2004).","journal-title":"Ann. Neurol."},{"key":"41429_CR8","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.nicl.2017.04.025","volume":"15","author":"S Bullich","year":"2017","unstructured":"Bullich, S. et al. Optimized classification of 18F-Florbetaben PET scans as positive and negative using an SUVR quantitative approach and comparison to visual assessment. Neuroimage Clin. 15, 325\u2013332 (2017).","journal-title":"Neuroimage Clin."},{"key":"41429_CR9","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s00259-015-3228-x","volume":"43","author":"E Morris","year":"2016","unstructured":"Morris, E. et al. Diagnostic accuracy of (18)F amyloid PET tracers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Eur. J. Nucl. Med. Mol. Imaging 43, 374\u2013385 (2016).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"41429_CR10","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1001\/jama.2009.1064","volume":"302","author":"N Mattsson","year":"2009","unstructured":"Mattsson, N. et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. J.A.M.A. 302, 385\u2013393 (2009).","journal-title":"J.A.M.A."},{"key":"41429_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/WAD.0000000000000184","volume":"31","author":"SA Park","year":"2017","unstructured":"Park, S. A. et al. Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease in South Korea. Alzheimer Dis. Assoc. Disord. 31, 13\u201318 (2017).","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"41429_CR12","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1212\/WNL.0000000000003050","volume":"87","author":"JP Chhatwal","year":"2016","unstructured":"Chhatwal, J. P. et al. Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly. Neurology 87, 920\u2013926 (2016).","journal-title":"Neurology"},{"key":"41429_CR13","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr.","year":"2018","unstructured":"Jack, C. R. Jr. et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 14, 535\u2013562 (2018).","journal-title":"Alzheimers Dement."},{"key":"41429_CR14","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.neurobiolaging.2009.07.002","volume":"32","author":"SM Landau","year":"2011","unstructured":"Landau, S. M. et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol. Aging 32, 1207\u20131218 (2011).","journal-title":"Neurobiol. Aging"},{"key":"41429_CR15","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/cercor\/bhn113","volume":"19","author":"BC Dickerson","year":"2009","unstructured":"Dickerson, B. C. et al. The cortical signature of Alzheimer\u2019s disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb. Cortex 19, 497\u2013510 (2009).","journal-title":"Cereb. Cortex"},{"key":"41429_CR16","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13195-017-0324-0","volume":"9","author":"MJ Wang","year":"2017","unstructured":"Wang, M. J. et al. Oligomeric forms of amyloid-\u03b2 protein in plasma as a potential blood-based biomarker for Alzheimer\u2019s disease. Alzheimers Res. Ther. 9, 98, https:\/\/doi.org\/10.1186\/s13195-017-0324-0 (2017).","journal-title":"Alzheimers Res. Ther."},{"key":"41429_CR17","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","volume":"14","author":"MM Mielke","year":"2018","unstructured":"Mielke, M. M. et al. Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement. 14, 989\u2013997 (2018).","journal-title":"Alzheimers Dement."},{"key":"41429_CR18","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson, B. et al. CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol. 15, 673\u2013684 (2016).","journal-title":"Lancet Neurol."},{"key":"41429_CR19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13195-017-0248-8","volume":"9","author":"JC Park","year":"2017","unstructured":"Park, J. C. et al. Chemically treated plasma A\u03b2 is a potential blood-based biomarker for screening cerebral amyloid deposition. Alzheimers Res. Ther. 9, 20, https:\/\/doi.org\/10.1186\/s13195-017-0248-8 (2017).","journal-title":"Alzheimers Res. Ther."},{"key":"41429_CR20","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/jgs.15048","volume":"6","author":"DR Adams","year":"2018","unstructured":"Adams, D. R. et al. Olfactory Dysfunction Predicts Subsequent Dementia in Older USAdults. J. Am. Geriatr. Soc. 6, 140\u2013144 (2018).","journal-title":"J. Am. Geriatr. Soc."},{"key":"41429_CR21","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3233\/JAD-122443","volume":"37","author":"N Wu","year":"2013","unstructured":"Wu, N., Rao, X., Gao, Y., Wang, J. & Xu, F. Amyloid-\u03b2 deposition and olfactory dysfunction in an Alzheimer\u2019s disease model. J. Alzheimers Dis. 37, 699\u2013712 (2013).","journal-title":"J. Alzheimers Dis."},{"key":"41429_CR22","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.neures.2013.03.016","volume":"76","author":"N Kameshima","year":"2013","unstructured":"Kameshima, N., Yanagisawa, D. & Tooyama, I. \u03b2-Amyloid peptide (1\u201340) in the brain reaches the nasal cavity via a non-blood pathway. Neurosci. Res. 76, 169\u2013172 (2013).","journal-title":"Neurosci. Res."},{"key":"41429_CR23","doi-asserted-by":"publisher","first-page":"737","DOI":"10.3233\/JAD-170962","volume":"62","author":"Z Liu","year":"2018","unstructured":"Liu, Z. et al. Development of a High-Sensitivity Method for the Measurement of Human Nasal A\u03b242, Tau, and Phosphorylated Tau. J. Alzheimers Dis. 62, 737\u2013744 (2018).","journal-title":"J. Alzheimers Dis."},{"key":"41429_CR24","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.archger.2007.08.012","volume":"47","author":"C Han","year":"2008","unstructured":"Han, C. et al. An adaptation of the Korean mini-mental state examination (K-MMSE) in elderly Koreans: Demographic influence and population-based norms (the AGE study). Arch. Gerontol. Geriatr. 47, 302\u2013310 (2008).","journal-title":"Arch. Gerontol. Geriatr."},{"key":"41429_CR25","doi-asserted-by":"publisher","unstructured":"Ben Bouall\u00e8gue, F., Mariano-Goulart, D., Payoux, P. & Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI). Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer\u2019s disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database. Alzheimers Res. Ther. 9, 32, https:\/\/doi.org\/10.1186\/s13195-017-0260-z (2017).","DOI":"10.1186\/s13195-017-0260-z"},{"key":"41429_CR26","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1212\/01.wnl.0000271090.28148.24","volume":"69","author":"JA Schneider","year":"2007","unstructured":"Schneider, J. A., Arvanitakis, Z., Bang, W. & Bennett, D. A. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 69, 2197\u20132204 (2007).","journal-title":"Neurology"},{"key":"41429_CR27","first-page":"571","volume":"72","author":"JB Toledo","year":"2015","unstructured":"Toledo, J. B. et al. Nonlinear association between cerebrospinal fluid and Florbetapir F-18 \u03b2-amyloid measures across the spectrum of Alzheimer disease. J.A.M.A. Neurol. 72, 571\u2013581 (2015).","journal-title":"J.A.M.A. Neurol."},{"key":"41429_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/srep33694","volume":"6","author":"YK Yoo","year":"2016","unstructured":"Yoo, Y. K. et al. Ultra-sensitive detection of brain-derived neurotrophic factor (BDNF) in the brain of freely moving mice using an interdigitated microelectrode (IME) biosensor. Sci. Rep. 6, 33694, https:\/\/doi.org\/10.1038\/srep33694 (2016).","journal-title":"Sci. Rep."},{"key":"41429_CR29","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.bios.2016.01.086","volume":"80","author":"AK Yagati","year":"2016","unstructured":"Yagati, A. K. et al. Silver nanoflower-reduced graphene oxide composite based micro-disk electrode for insulin detection in serum. Biosens. Bioelectron. 80, 307\u2013314 (2016).","journal-title":"Biosens. Bioelectron."},{"key":"41429_CR30","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1176\/ajp.142.6.781-a","volume":"142","author":"M Serby","year":"1985","unstructured":"Serby, M., Corwin, J., Conrad, P. & Rotrosen, J. Olfactory dysfunction in Alzheimer\u2019s disease and Parkinson\u2019s disease. Am. J. Psychiatry 142, 781\u2013782 (1985).","journal-title":"Am. J. Psychiatry"},{"key":"41429_CR31","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1001\/archneur.55.1.84","volume":"55","author":"RI Mesholam","year":"1998","unstructured":"Mesholam, R. I., Moberg, P. J., Mahr, R. N. & Doty, R. L. Olfaction in neurodegenerative disease: a meta-analysis of olfactory functioning in Alzheimer\u2019s and Parkinson\u2019s diseases. Arch. Neurol. 55, 84\u201390 (1998).","journal-title":"Arch. Neurol."},{"key":"41429_CR32","first-page":"93","volume":"73","author":"RO Roberts","year":"2016","unstructured":"Roberts, R. O. et al. Association between olfactory dysfunction and amnestic mild cognitive impairment and Alzheimer disease dementia. J.A.M.A. Neurol. 73, 93\u2013101 (2016).","journal-title":"J.A.M.A. Neurol."},{"key":"41429_CR33","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1096\/fj.09-150359","volume":"24","author":"H Fukumoto","year":"2010","unstructured":"Fukumoto, H. et al. High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J. 24, 2716\u20132726 (2010).","journal-title":"FASEB J."},{"key":"41429_CR34","doi-asserted-by":"publisher","first-page":"e111899","DOI":"10.1371\/journal.pone.0111899","volume":"9","author":"NJ Izzo","year":"2014","unstructured":"Izzo, N. J. et al. Alzheimer\u2019s therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2\/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity. PLoS One. 9, e111899, https:\/\/doi.org\/10.1371\/journal.pone.0111899 (2014).","journal-title":"PLoS One."},{"key":"41429_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9997","volume":"6","author":"HY Kim","year":"2015","unstructured":"Kim, H. Y. et al. EPPS rescues hippocampus-dependent cognitive deficits in APP\/PS1 mice by disaggregation of amyloid-\u03b2 oligomers and plaques. Nat. Commun. 6, 8997, https:\/\/doi.org\/10.1038\/ncomms9997 (2015).","journal-title":"Nat. Commun."},{"key":"41429_CR36","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging\u2013Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 7, 263\u2013269 (2011).","journal-title":"Alzheimers Dement."},{"key":"41429_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-017-0869-6","volume":"15","author":"R Bordet","year":"2017","unstructured":"Bordet, R. et al. Towards the concept of disease-modifier in post-stroke or vascular cognitive impairment: a consensus report. BMC Med. 15, 107, https:\/\/doi.org\/10.1186\/s12916-017-0869-6 (2017).","journal-title":"BMC Med."},{"key":"41429_CR38","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1093\/brain\/awn234","volume":"131","author":"DS Knopman","year":"2008","unstructured":"Knopman, D. S. et al. Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. Brain 131, 2957\u20132968 (2008).","journal-title":"Brain"},{"key":"41429_CR39","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1080\/13803395.2015.1073227","volume":"37","author":"LF Vasconcellos","year":"2015","unstructured":"Vasconcellos, L. F. & Pereira, J. S. Parkinson\u2019s disease dementia: Diagnostic criteria and risk factor review. J. Clin. Exp. Neuropsychol. 37, 988\u2013993 (2015).","journal-title":"J. Clin. Exp. Neuropsychol."},{"key":"41429_CR40","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1037\/1040-3590.3.2.168","volume":"3","author":"KJ Christensen","year":"1991","unstructured":"Christensen, K. J., Multhaup, K. S., Nordstrom, S. & Voss, K. A cognitive battery for dementia: Development and measurement characteristics. Psychol. Asses. 3, 168\u2013174 (1991).","journal-title":"Psychol. Asses."},{"key":"41429_CR41","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.3346\/jkms.2010.25.7.1071","volume":"25","author":"HJ Ahn","year":"2010","unstructured":"Ahn, H. J. et al. Seoul Neuropsychological Screening Battery-dementia version (SNSB-D): a useful tool for assessing and monitoring cognitive impairments in dementia patients. J. Korean Med. Sci. 25, 1071\u20131076 (2010).","journal-title":"J. Korean Med. Sci."},{"key":"41429_CR42","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/alr.21133","volume":"3","author":"DY Cho","year":"2013","unstructured":"Cho, D. Y. et al. Expression of dual oxidases and secreted cytokines in chronic rhinosinusitis. Int. Forum Allergy Rhinol. 3, 376\u2013383 (2013).","journal-title":"Int. Forum Allergy Rhinol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41429-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41429-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41429-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T08:02:38Z","timestamp":1671264158000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41429-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,21]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["41429"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-41429-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,21]]},"assertion":[{"value":"1 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"4966"}}